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 “Science is more than a body of knowledge. It is a way of thinking; a way of skeptically 
interrogating the universe with a fine understanding of human fallibility. 
If we are not able to ask skeptical questions, to interrogate those who tell us that something 
is true, to be skeptical of those in authority, then, we are up for grabs…” 
 
Carl Sagan 
May 27th 1996 
 
 
 
 
  
ABSTRACT 
Effective vaccines for many dangerous infectious diseases are still lacking. An improved 
understanding of the mechanisms that determine the quality of vaccine responses is essential 
to guide future attempts to design effective vaccines. This thesis aimed to characterize the 
early and late immune responses of different clinically relevant vaccine platforms. All studies 
were performed in the non-human primate (NHP) model due to their physiological and 
immunological similarities to humans.  
 
Protein subunit vaccines are commonly used when live attenuated vaccines are unsafe. 
Adjuvants are often needed in protein subunit vaccines to stimulate sufficiently potent 
immune responses. In paper I we developed an in vivo model to examine the initial 
immunological events after vaccine administration into the muscle. Specifically, we studied 
the mechanisms of the adjuvants Alum, MF59 and Alum-TLR7. We found that all adjuvants 
induced rapid infiltration of immune cells at the site of vaccine injection. Alum-TLR7 and 
MF59 showed stronger adaptive immune profiles compared to Alum, including higher 
antibody titers, better neutralization and a stronger germinal center (GC) response. However, 
their innate immune activation was very different. Alum-TLR7 exclusively induced a type I 
interferon response and excelled at dendritic cell maturation while MF59 promoted 
neutrophil recruitment to the vaccine draining lymph nodes (LNs). 
 
In paper II-III we studied mRNA-based vaccines which have emerged as promising 
candidates against several diseases including Zika and influenza. In paper II we used 
fluorescently labeled lipid nanoparticles (LNP) encapsulating mRNA encoding for the 
fluorescent protein mCitrine, for tracking of vaccine uptake and mRNA translation 
separately. We found a rapid infiltration of immune cells to the site of injection as well as 
uptake and translation of the mRNA into antigen with both intradermal and intramuscular 
immunizations. A strong type I interferon response was induced at the site of injection and 
the draining LNs. Priming of T cells occurred in the vaccine-draining LNs. In paper III we 
investigated the adaptive immune profile of a mRNA vaccine encoding influenza 
hemagglutinin. Immunization induced a quick B cell response including vaccine-specific 
memory B cells in blood and plasma cells in the bone marrow. Formation of GCs was 
detected in the vaccine draining LNs. Circulating vaccine-specific CXCR3+ T follicular 
helper cells, associated with a Th1 response, transiently appeared in the blood and correlated 
with antibody avidity in serum.  
 
Finally, in paper IV, we focused on the methodological advancements of GC analysis. LNs 
were divided in two and each half was analyzed by either immunohistology or flow 
cytometry. We propose a method to analyze and present GC data to make a direct comparison 
possible between studies regardless of the technique. Altogether, the data presented in the 
thesis will add to the understanding of how vaccine responses are initiated and regulated. 
Ultimately this will help in the development of new or improved vaccines.  
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1 INTRODUCTION TO VACCINES 
1.1 HISTORY OF VACCINES 
 
Vaccines are among the greatest medical interventions in history to transform global health. 
Edward Jenner (1749-1823) revolutionized health care by learning that milk maidens infected 
by cowpox were resistant to smallpox (1). In one of the first documented vaccinations, 
Edward Jenner inoculated humans with cowpox to induce resistance to smallpox, a pivotal 
event for the field of immunology (1, 2). In the 19th century, another major discovery was 
made by Louis Pasteur (1822-1895) who introduced the “Germ Theory of Disease”, replacing 
the previous theory of “Spontaneous generation”. Within the new paradigm, where 
microorganisms caused disease instead of vice versa, strategies to prevent infection by 
microorganisms could be implemented. Emile Roux (1853-1933), Pasteur’s assistant and 
successor, later discovered toxins from diphtheria as an agent of disease, an important finding 
for future toxoid vaccines. Two years later Emil Von Behring (1854-1917) and Shibasabura 
Kitasato (1853-1931) developed a treatment for diphtheria, based on serum from horses 
immunized with attenuated diphtheria bacteria (3, 4). Kitasato and Behring were the first to 
introduce the concept of antibodies and the latter was awarded the Nobel Prize in 1901 for 
the new treatment of diphtheria. Collectively, these discoveries, among others, laid the 
ground for the main strategy of vaccine development; isolate the microbe or its toxins, 
prepare vaccine formulations with antigens of said microbe or toxin, and administer them to 
induce protective antibodies. Early success with this strategy was tremendous with a 
substantial decline in many diseases, including the historical accomplishment of smallpox 
eradication in 1980 (5). Yet there are still many infectious diseases for which there are no 
effective vaccines, such as tuberculosis, malaria and human immunodeficiency virus (HIV). 
To combat these diseases, an improved understanding of the mechanisms of action by 
vaccines is needed to facilitate rational development of the next generation of vaccines.
   
1.2 TYPES OF VACCINES 
 
There are currently many different types of vaccines that all work by activating and 
expanding cells with the antigen-specificity of interest (3). Although new promising vaccines 
that function by generating cytotoxic CD8 T cells are being developed, most vaccines work 
by eliciting protective antibodies (6). Differently formulated vaccines are grouped into 
vaccine “platforms” with their own distinct advantages, these are summarized in Figure 1. 
Live attenuated vaccines are whole pathogens that have been weakened to reduce 
proliferation and infectious potential in humans. The rubella and yellow fever vaccines are 
examples of live attenuated formulations. Such vaccines most closely resemble natural 
infection and have thus far proven to be the most effective means of vaccination, requiring 
few if any boost vaccinations, along with high protection (7). However, live attenuated 
vaccines pose the risk of reverting back to a pathogenic form and therefore cannot be used 
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against pathogens such as HIV and Ebola. Additionally, they cannot be used in 
immunocompromised individuals due to safety reasons. Another problem with vaccines 
containing live pathogens is the need for cold-chain storage, making the distribution of the 
vaccine exceedingly difficult (8). 
           
 
Inactivated vaccines are produced by destroying the pathogen with radiation, heat or 
chemicals, rendering the pathogen harmless while keeping intact the antigens recognized by 
the immune system. Examples of such vaccines are influenza, Hepatitis A and poliovirus 
vaccines (9). Conjugate vaccines are designed from the bacterial coat and are co-administered 
with a carrier protein. A common bacteria, Streptococcus pneumoniae, is the target of such 
vaccines (10). Vaccination with weakened toxins prevents toxin-induced mortality and 
morbidity, one such being neurotoxin produced by Clostridium tetani (10). A recent vaccine 
platform licensed for human use is virus-like particle vaccines. They are made out of proteins 
that fold together into spheres that closely resemble the virus, but are without genomic 
material and are therefore incapable of proliferation. Virus-like particle vaccines were first 
licensed against Hepatitis B followed by human papillomavirus (11).  
 
This thesis contains studies of vaccines against HIV and influenza. The main purpose of these 
studies was to gain a more detailed understanding of the immunological mechanisms of the 
different vaccine platforms used. In study I, protein subunit vaccines were used. Such 
vaccines contain only parts of the pathogen and therefore lack other microbial 
immunostimulators. Adjuvants, from Latin “to help”, are used as artificial 
immunostimulators to improve vaccine efficacy (12). Examples of protein subunit vaccines 
are annual influenza vaccines and HIV candidate vaccines. In study II and III mRNA 
vaccines were investigated. mRNA vaccines belong to a family of emerging vaccines that 
are not yet commonly used in a clinical setting but show great potential in scientific research 
and clinical trials (13).  
 
Figure 1: Vaccine platforms and their current application in humans. 
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2 AIMS OF THESIS 
 
The general aim of this thesis was to better understand the innate and adaptive immune 
response induced by different vaccine platforms. Information on the type of immune response 
induced by vaccines is essential for their future improvement.  The specific aims were: 
 
Paper I: To investigate the innate and early adaptive immune response induced by three 
clinically relevant adjuvants; Alum, Alum-TLR7 and MF59 
 
Paper II: To study the early immune response to mRNA vaccines 
 
Paper III: To study the adaptive immune response to a mRNA vaccine encoding influenza 
hemagglutinin (HA) 
 
Paper IV: To develop a method for immunohistological analysis of germinal centers that is 
comparable to flow cytometry  
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3 IMMUNOLOGY 
 
3.1 INTRODUCTION 
 
Our immune system has developed through the trial and error of evolution by natural 
selection to recognize harmless self from harmful non-self and self. The latter two include 
pathogens such as bacteria and viruses, as well as endogenous cells that are damaged or have 
turned cancerous. The capacity of the immune system to effectively recognize and neutralize 
a countless variety of such threats is a marvelous feat of nature. To achieve this, the immune 
system is equipped with two main pathways of pathogen recognition that can be broadly 
divided into innate and adaptive immunity (14). The innate immune system functions 
primarily by a set of receptors against common antigens of pathogens, an evolutionary 
memory against pathogens that have co-evolved with us (15). However, in an ever-changing 
environment, new pathogens can arise at any time, and current pathogens continuously 
develop new strategies to evade our fixed means of pathogen recognition. A prime example 
of this is the HIV, which hides its epitopes, i.e. the part of its antigens which is being 
recognized by the immune system, by covering them with non-immunogenic glycans. 
Adaptive immunity provides an alternative strategy by attempting to detect any structure that 
is not considered self and react to it if necessary. This process is slower since there can only 
be very few cells specific against any potential antigen. However, it is also more flexible 
since these cells can rapidly expand to large numbers of effector and memory cells with an 
incredible capacity to neutralize dangerous pathogens.  
3.2 INNATE IMMUNITY 
 
Innate immunity provides the first line of defense against invading pathogens at the sites 
where pathogens are usually encountered; mucosal tissues, skin and airways (14). Since the 
probability of encountering pathogens at these sites is high, more immune cells reside at these 
sites than in tissues that are less likely to encounter antigens, such as muscles (16). 
Additionally, innate immune cells are important for maintaining homeostasis within the 
body, contributing to both tissue repair and the control of commensal microbes (15).  
 
The innate immune system detects and neutralizes pathogens via fixed systems consisting of 
cells, complement proteins and antimicrobial peptides (17). Pattern recognition receptors 
(PRRs) on innate immune cells recognize common features of pathogens. Activation of PRRs 
leads to the release of proinflammatory cytokines, including TNF and interleukin-6 (IL) (18). 
There are 4 main families of PRRs: Toll-like receptors (TLRs), RIG I-like receptors, 
nucleotide-binding oligomerization-like receptors and C-type lectin receptors (19). 
Depending on which PRR is activated, different innate immune responses are initiated to 
efficiently combat the invading pathogens. This also shapes adaptive immunity by the type 
of cytokines that are produced. Due to their ability to induce inflammation and shape adaptive 
immunity, the ligands for PRRs are utilized as vaccine adjuvants.  
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The initial recognition of pathogens by PRRs leads to the initiation of inflammation which is 
clinically characterized by rubor (dilation of blood vessels), tumor (swelling), dolor (pain), 
calor (temperature increase due to an influx of blood) and function laesa (loss of function). 
Dilation of blood vessels and the production of chemokines lead to extravasation of innate 
immune cells to the site of inflammation. The newly arrived innate immune cells produce 
more cytokines to amplify the immune response. Neutrophils and monocytes from circulation 
(or tissue resident macrophages) infiltrate first and use scavenger receptors to phagocytose 
microorganisms and degrade them (20). Neutrophils can also release their granules 
containing antimicrobial products and neutrophil extracellular traps consisting of DNA to 
neutralize invading pathogens (21). Of particular importance are antigen presenting cells 
(APCs) loaded with antigen, which is presented on the cell surface to the cells of the adaptive 
immune system. The cells most efficient at bridging the innate and adaptive immune system 
are professional APCs such as dendritic cells (DCs).  
3.3 DENDRITIC CELLS 
 
DCs are often called the sentinels of the immune system. They are specialized at taking up, 
processing and presenting antigens (22). There are two main categories of DCs; myeloid 
classic DCs (cDCs) efficient at antigen presentation and plasmacytoid DCs (PDCs) which 
excel at producing type I interferons (IFN) in response to viruses.  
 
cDCs are a heterogeneous group of cells that reside in most tissues (23). Apart from the 
tissue-resident DCs such as Langerhans cells, cDCs and can be divided in two main subsets: 
cDC1s characterized by their expression of Batf3, XCR1 or CD141 and cDC2s characterized  
by their expression of IRF4, CD172 or CD1c (23). Traditionally cDC1 have been considered 
to excel at antigen cross-presentation over cDC2s, but these differences might not be as 
profound in humans as in mice (24). Generally, cDC1s are believed to participate mainly in 
responding to intracellular pathogens, while cDC2s respond to intra- and extracellular 
pathogens (23). cDCs express a large variety or PRRs to sense injury and pathogenic 
microbes. cDCs orchestrate the immune system by inducing tolerance to self-antigens and by 
the activation of naïve T cells. There are several factors contributing to their excellent ability 
at performing these tasks including: Their strategic localization in both lymphoid and non-
lymphoid organs with a constant supply of self and foreign antigens, their high capacity for 
antigen processing and presentation (25, 26), their ability to migrate with antigen to draining 
LNs (27) and the fact that they excel at priming naïve T cells (28). Due to their unique ability 
to excel at activating T cells and tailoring them to combat specific kinds of threats, DCs are 
one of the main cell types of interest in the study of vaccines. 
 
PDCs reside mainly in blood and LNs. They differ from cDCs in that they are not efficient 
at taking up antigen and they express low levels of major histocompatibility complex (MHC) 
class II and co-stimulatory molecules (29). Also unlike cDCs that express a wide range of 
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TLRs, PDCs mainly express TLR7/9. Although PDCs are very scarce compared to cDCs, 
they make up for their low numbers by their unique capability to produce vast amounts of 
type I IFNs. This provides protection against intracellular pathogens and skews the adaptive 
immune response towards an intracellular adapted T helper 1 (Th1) profile (30).  
3.4 ADAPTIVE IMMUNITY 
 
Pathogens that evade our innate immune mechanisms are often cleared by our adaptive 
immune response, which in contrast to the innate immune response is flexible rather than 
fixed (14). The primary cells of adaptive immunity, B cells and T cells, randomly generate 
unique receptors on their surfaces that specifically target specific epitopes of antigens (14). 
B cells and T cells specific for self-antigens are deleted through central and peripheral 
tolerance mechanisms. If these mechanisms fail, autoimmune diseases arise (31). Upon 
detection of their cognate antigen and proper stimulation, B cells or T cells are activated and 
proliferate. Once the infection is cleared some of the expanded cells will persist as 
immunological memory or effector cells to enhance protection from reinfection of the same 
pathogen. The process of clonally expanding B cells and T cells specific against vaccine 
antigens is the central mechanism of vaccination (32). 
 
Adaptive immunity is broadly divided into humoral and cellular immunity. Cellular 
immunity is mediated by CD8+ T cells that kill infected cells and CD4+ helper T cells that 
exhibit helper functions to support innate cells, CD8+ T cells and B cells. While CD8+ T 
cells are generally not the mediators of vaccine-induced protection, B cells are central (32). 
CD4+ T cells are therefore crucial for vaccine responses due to their ability to help B cells. B 
cells are the effector cells of humoral immunity and produce antibodies, also called 
immunoglobulins (Ig) (33). Upon activation, B cells differentiate into memory B cells or 
plasma cells that are capable of producing and secreting large quantities of antibodies (34). 
Antibodies will bind to their specific antigen and exert one of several functions depending 
on the type of antibody, including opsonization by phagocytes, activation of the complement 
cascade or antigen-dependent cell-mediated cytotoxicity (35). Almost all vaccines function 
by eliciting durable antibody titers that protect from infection or severe disease. Sustainable 
antibodies produced by long-lived plasma cells residing in the bone marrow (BM) are thus 
critical for maintaining long-term protection after vaccination (33). 
3.5 INTERACTION BETWEEN INNATE AND ADAPTIVE IMMUNITY 
 
A core theme of this thesis is the co-operation between innate and adaptive immunity. Such 
co-operation is eloquently displayed by the activation of complement (innate immunity) by 
antibodies (adaptive immunity), to assemble the membrane attack complex (35, 36). Innate 
immunity also functions to initiate the adaptive immune response by providing antigens and 
the right inflammatory signals. Naïve B cells and T cells originate in the BM and mature in 
the BM or thymus respectively before entering circulation (14). Guided by the chemokine 
receptors such as CCR7 and CXCR5 they migrate from the circulation to secondary lymphoid 
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organs in search of their cognate antigen (37, 38). However, the cognate antigen must first 
arrive at secondary lymphoid organs to be given to B cells and presented to T cells by innate 
immune cells. Once DCs have taken up antigen in the periphery, they downregulate 
chemokine receptors such as CCR1 and CCR5 and upregulate CCR7 to migrate towards 
draining LNs (39). DCs present processed antigens on MHC class II to CD4+ T cells which 
will be described in detail later. Antigens also arrive at the LNs through lymphatic drainage 
with innate immune cells or freely diffused in lymphatic fluid. A group of macrophages lining 
the sub-capsular sinus efficiently take up antigen and shuttle them on to B cells that transport 
them to B cell follicles. Once T cells and B cells are activated within the LN some of them 
enter the germinal center (GC) reaction, which as will be discussed later is crucial for the 
generation of high affinity antibodies. The GC reaction is also dependent on innate immune 
cells such as follicular dendritic cells (FDCs) which are stromal cells located in GC (29). Due 
to this close connection between innate and adaptive immunity, there is a great effort in 
understanding and targeting innate immune cells to enhance adaptive immunity. DCs have 
received particular attention since they are important APCs (40, 41). 
3.6 B CELL DIFFERENTIATION AND ACTIVATION 
 
Naïve B cells are generated from the BM. Before exiting the BM, developing B cells must 
create a B cell receptor (BCR) with random specificity by V(D)J recombination. Within the 
BM, strong binding of the BCR indicates an autoimmune BCR, since only self-antigen are 
presumed to be in the BM. This leads to the negative selection of that B cell clone (42). 
Conversely, no binding or activation of the BCR gives no proof that the BCR works, which 
also results in the deletion of this B cell clone (42). Hence B cells need a functioning BCR 
with no or low self-reactivity in order to enter circulation. Once in circulation B cells migrate 
back and forth between the lymphatic and vascular systems in search of its cognate antigen. 
The organs of the body are all draining to LNs where the antigens are concentrated by an 
intricate network of stromal and innate immune cells. This greatly increases the probability 
that a B cell will encounter its cognate antigen by probing the LNs of the body. The random 
generation of B cell specificity ensures that a wide variety of specificities are represented, 
however very few cells for each specificity are generated. B cells are APCs and present 
peptides from their cognate antigen on MHC class II after internalization of the antigen by 
BCR binding (43). CD4+ helper T cells that are specific for an epitope on the same antigen 
will then provide help to the B cells by activating CD40 with CD40L and by the production 
of cytokines. The activation of naïve B cells by CD4+ helper T cells also leads to switching 
from IgM to IgG, IgE or IgA, depending on which cytokine is provided, in a process termed 
class switch recombination. B cells can also be activated without T cell help, in a process 
called T independent activation. This is usually achieved by activation of the BCR in 
combination with TLR activation, or activation by antigens with highly repetitive structures 
that cause cross-linking of the BCR (44). This activation, however, is generally considered 
not to cause antibody class switch and usually results in low-affinity IgM antibodies being 
secreted. Overall the B cell is destined for one of three general pathways after T cell-
 16 
dependent activation; 1. Become a short or long-lived plasma cell 2. Become a memory B 
cell or 3. Enter the GC reaction. The end goal of most vaccination strategies is the induction 
of long-lived plasma cells and memory B cells with the right quality of antibodies. Hence a 
fundamental understanding of the mechanisms that determine B cell fate after an encounter 
with its cognate antigen is important to our future attempts to design new better vaccines.  
3.7 T CELL DIFFERENTIATION AND ACTIVATION 
 
T cells undergo their initial selection in the thymus. T cells are generated with a T cell 
receptor (TCR) with a random specificity. For CD4 T cells to develop, the TCR needs to 
recognize MHC class II, failure to do this results in apoptosis (45).  The TCR of newly 
generated T cells is tested within the thymus (45). To prevent autoimmunity, T cells that bind 
antigen too strongly within the thymus will undergo apoptosis or differentiate into regulatory 
T cells (45, 46). This central tolerance mechanism ensures that T cells entering the circulation 
have a viable TCR that has a low probability of causing autoimmunity. 
 
Once outside the thymus, T cells circulate the body in search for their cognate antigen. Unlike 
B cells that recognize antigens in their native form, T cells only recognize their antigen when 
it is degraded into peptides and presented on MHC class II molecules. Although several cell-
types express MHC class II and can present antigen to CD4 T cells, only professional APCs 
are able to efficiently prime naïve T cells (Figure 2) (47). Priming is achieved by three 
signals. Signal one: the binding of TCR to MHC class II molecule and peptide complex. 
Signal two: the activation of the CD28 receptor by CD80/86 on APCs. And signal three: 
cytokines secreted by the APC.  
 
Signal three, in particular, has the additional advantage of being able to shape the T cell into 
different subtypes, most classically termed Th1, Th2 and Th17 (48). Additionally, Th9 and 
Th22 subtypes have also been characterized and are thought to protect against cancer and 
bacteria respectively. However, these subtypes are less defined and will not be further 
discussed in this thesis (48). Since detailed differentiation studies are more suited for mouse 
studies, where knockout models are available, a lot of our current knowledge of Th cell 
differentiation comes from mice. However, it is important to note that while Th1 and Th2 
differentiation are very similar between mouse and humans, Th17 differentiation seems to 
differ between the species (48). Here the differentiation mechanisms for human T cells will 
be discussed since it is most applicable to the studies of the thesis.  
 
Th1 cells are mainly thought to enhance protection against intracellular pathogens. In the 
1990s it was discovered that IL12 was instrumental to Th1 differentiation, and the 
transcription factor T-bet was revealed to be crucial for the phenotype in the year 2000 (49). 
Additionally, IFNγ promotes the expression of itself and activates STAT1 which increases 
T-bet expression (49).  
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Th2 cells are associated with 
parasite infections and allergy (48). 
They secrete IL-4, IL-5 and IL-13. 
The differentiation of Th2 cells is 
less clearly understood than that of 
Th1 and Th17 cells. The main 
cytokine for Th2 differentiation, 
IL4, which turns on the Th2 
transcription factor GATA3 is not 
produced in large amount by DCs 
(50). Hence it is possible that other 
innate immune cells play a crucial 
role in the differentiation of Th2 
cells, and some studies suggest that 
full differentiation is only achieved 
after leaving the LN to sites of 
inflammation, where innate immune 
cells can provide the necessary IL4. 
In addition, Th2 cells have 
traditionally been thought to excel at 
B cell help although this is now 
more attributed to T follicular helper 
cells (TFH) (51, 52). 
 
Th17 cells are involved in several autoimmune disorders and provide defense against 
extracellular bacteria and fungi. Their characteristic cytokine IL17 induces the production of 
chemokines and other cytokines that leads to the recruitment of neutrophils and monocytes 
(53). Th17 cells express the chemokine receptor CCR6 (54). Th17 differentiation is 
controlled by the transcription factor RORγt which is upregulated upon stimulation with 
TGFβ, other cytokines that increase RORγt expression but are not essential for its induction 
are IL6, IL21, IL23 and IL1β (55, 56).  
 
4 GERMINAL CENTERS 
 
4.1 THE GERMINAL CENTER RESPONSE 
 
GCs were described more than 125 years ago by Walther Flemming and were first believed 
to be the birthplace of lymphocytes (57). Today we know they are rather the cradle of 
differentiated high-affinity B cells. It has long been known that repeated immunizations 
increase the affinity of antibodies against administered antigens in a process termed affinity 
Figure 2: T cell activation by an antigen presenting 
dendritic cell. 
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maturation (58, 59). A better understanding of this phenomenon was reached since it was 
discovered that affinity maturation was not achieved by better selection of B cells with 
appropriate V(D)J rearrangement, but rather by mutations into V(D)J sequences of lower 
affinity (60-63). The mutations to the BCR are driven by the activation-induced deaminase 
(AID) enzyme, which specifically mutates the BCR upon cell division in a process termed 
somatic hypermutation (SHM) (35, 64, 65). The AID enzyme sometimes induces off-target 
mutations, occasionally in oncogenes, which increase the risk for B cell lymphomas (66). 
The GC arises in a B cell follicle with naïve B cells. When a B cell follicle is occupied by 
rapidly dividing GC B cells, naïve B cells that reside in the follicle are pushed away to the 
edges of the GC, forming the B cell mantle (57). GCs develop around 4-6 days after antigen 
administration and take a few days more to fully mature (67). In the actual GC, two main 
areas are found, called the dark zone and the light zone. B cell proliferation and SHM occurs 
in the dark zone, whilst TFH dependent selection of high-affinity B cells occurs in the light 
zone. High-affinity B cell clones are selected in a Darwinian evolution by natural selection 
like process, in the micro-cosmos of the secondary lymphoid organs. If the GC B cell fails to 
find its cognate antigen or performs poorly at antigen presentation it undergoes apoptosis. 
However, after successful presentation of its antigen to a TFH cell the GC B cell is sent back 
to the dark zone for additional rounds of proliferation. This process is then repeated so that 
newly generated GC B cells continuously cycle back and forth between the dark zone and 
the light zone, with higher affinity clones being selected for survival. This is how the GC 
achieves its main goal of affinity maturation. GC B cells that receive proper stimulation in 
the light zone are then selected to become either memory B cells or short or long lived plasma 
cells (57). To me, the GC is one of the most fascinating structures in the human body. It is at 
the center of vaccine immunology due to its ability to produce affinity-matured long-lived 
memory B cells and plasma cells. An overview of the GC reaction is presented in figure 3. 
4.2 FOLLICULAR DENDRITIC CELLS 
 
FDCs were discovered in 1965 and are one of many stromal cells that participate in the 
underlying architecture of the LN (68). In this thesis, FDCs will be exclusively discussed due 
to their central role in the GC reaction. FDCs are generated from perivascular precursor cells 
and migrate to LNs to enable and support the GC reaction (69). FDCs are essential to the 
formation and maintenance of GCs, one major function being the recruitment of B cells and 
T cells via the production of CXCL13, the chemokine for CXCR5 (70, 71). Additionally, 
FDCs support GC B cell survival by the production of cytokines, such as B cell-activating 
factor (BAFF) or IL6 (72). One of the most interesting functions of FDCs is their ability to 
retain and cycle intact antigen on their cell surface (73). This provides B cells with intact 
antigens that they can use in their competition for TFH cell help (74). Additionally, since 
antigens can be bound to the surface of the FDC by complement receptors, the affinity of 
BCRs could perhaps be further assessed, since it has been shown that while there is no 
difference in antigen uptake between low and high-affinity BCRs for soluble antigen, high-
affinity BCRs have an advantage in uptake of antigens that are attached to a surface (75). 
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Antigens can reach FDCs in different ways depending on the size of the antigen and its 
previous interactions with the immune system. Antigens with a size less than 70 kDa can be 
transported directly via a conduit network to the FDCs (76). None of the vaccine formulations 
in this thesis are below this threshold. Larger antigens that have bound complement attached 
to them can be picked up by sub-capsular sinus macrophages by complement receptor 
recognition (70). The antigens are then transferred by the macrophage from the sub-capsular 
sinus to the opposite side of the macrophage facing B cell follicles. These antigens are picked 
up by naïve B cells in a non-cognate way by complement receptor binding and transport the 
antigen to FDCs (74, 77, 78). Since delivery of antigen to the FDCs is crucial for a strong 
GC reaction, the size of antigens and the way they interact with the complement system is 
thus of great interest in vaccine design. Mannose-binding lectins that recognize 
carbohydrates on microbes can bind complement (79). It was recently shown that sugars and 
valency of antigens on vaccine nanoparticles determined binding to mannose binding lectins, 
which influenced antigen transport to FDCs in a complement-dependent manner (80). This 
is a prime example of how a detailed understanding of the fundamental biology of stromal 
cells can have significant implications on vaccine design. It also underscores the need for 
continued research into the mechanisms of vaccination from the delivery of the vaccine to 
the binding of the antibody to its target epitope.  
4.3 GERMINAL CENTER B CELLS 
 
Since GC B cells are the precursor to affinity matured memory B cells and plasma cells, they 
are extensively investigated by immunologists. Before a GC is started naïve B cells are 
activated by the antigen and T cells at the B: T cell border. In the next phase, activated B 
cells migrate towards the B cell follicles in a CXCR5 dependent manner (57). After intense 
rounds of proliferation, some B cells enter the core of the B cell follicle to form an early GC 
(81). The GC B cells stay inside the GC due to changes in the expression of G protein-coupled 
receptors while their naïve B cell counterparts are pushed aside (82). Dark zone B cells have 
traditionally been called centroblasts and express high levels of CXCR4 (83). The chemokine 
for CXCR4, CXCL12 is believed to be provided by a network of reticular cells residing in 
the dark zone (84). Dark zone B cells express high levels of AID, which as previously 
mentioned induces mutations into the BCR upon cell division. Mutation rates are quick since 
GC B cells are among the fastest diving cells in the body with divisions every 6-12 hours 
(85, 86).  Any such mutation could either improve or worsen the affinity against the antigen. 
Subsequently, B cells enter the light zone by the down-regulation of chemokine receptors 
such as CXCR4 (82). Light zone GC B cells are called centrocytes and highly express 
activation markers such as CD86 (82). Light zone B cells compete for uptake of antigen from 
FDCs in an affinity-dependent manner (75). The B cells that manage to bind the most 
antigens and present it to TFH cells are given stimulation with CD40L, BAFF, IL4, IL21 (57, 
82). The B cells that do not receive enough stimulation instead undergo apoptosis and are 
engulfed by GC macrophages. The B cells that are given T cell help however, either re-enter 
the dark zone for additional rounds of proliferation or differentiate into either plasma cells or 
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memory B cells (82). Short-lived plasma cells function as immediate protection against on-
going infection and their role in vaccination is not known. Memory B cells patrol the body 
in search for their cognate antigen and upon renewed exposure they restart the GC reaction 
or proliferate and differentiate into plasma cells. There are three reasons why the memory B 
cell response is more effective than a naïve B cell response. 1) The number of memory B 
cells are at any given point higher than the number of naïve B cells specific for a certain 
antigen. 2) Memory B cells are more easily activated compared to naïve B cells. 3) Most 
memory B cells have already undergone affinity maturation in the GC and are thus likely 
already of high affinity at first antigen encounter. While memory B cells provide protection 
only after activation, long-lived plasma cells migrate to the BM where they continuously 
produce antibodies, independent of circulating antigen. Together, memory B cells and long-
lived BM plasma cells constitute the main end goals of vaccination (32).  
4.4 T FOLLICULAR HELPER CELLS 
 
TFH cells are crucial for an efficient GC reaction (51, 87). Several groups discovered that 
CXCR5+ T cells, now termed TFH cells, are efficient at activating B cells (38, 88). As 
previously mentioned, CXCR5 is the chemokine receptor for CXCL13 which promotes 
migration to B cell follicles in secondary lymphoid organs. TFH cells were shown to be 
different from previously discovered T cell subsets since they express little of their traditional 
transcription factors. TFH cells express high levels of BCL6, IL21, programmed death protein 
1 (PD1) and inducible T cell costimulator (ICOS) (89, 90).  BCL6 is the transcription factor 
driving the TFH phenotype (91-93). Today CXCR5 and PD1 surface markers are used to 
reliably detect TFH cells (94, 95).  TFH cells  are differentiated from CD4 T cells early on after 
antigen exposure (51). This requires antigen presentation by APCs that express ICOSL and 
OX40L (96). Interestingly immune complexes containing RNA, which activates TLR7 on 
APCs, upregulates OX40L which benefits TFH cell development (97). In humans, the 
cytokines that promote TFH cell differentiation are TGF-β, IL-12, and IL-23 (98). Powerful 
evidence to support the role of IL-12 and IL23 are the observations that humans lacking 
IL12R1β  have decreased numbers of circulating TFH cells, less memory B cells and lower 
avidity antibodies (99). IL2 and IL10 have been described as inhibitors of TFH development 
(100-102). The increasing production of IL2 in LNs after antigen exposure might therefore 
provide an obstacle for TFH cell differentiation. TFH cells might therefore be prone to develop 
early after antigen exposure, making sure that the humoral response is directed against the 
initial invading pathogen and not antigens from commensal bacteria that enter after protective 
barriers have been breached, that might not be as dangerous (51). Conversely, this might 
constitute a problem with dangerous secondary infections such as bacterial infections after 
influenza-induced pneumonia. To finalize and maintain their phenotype TFH cells need 
stimulation from B cells via CD80, CD86 and ICOSL (96). Without cognate B cells or 
proteins that enable long TFH cell B cell synapses such as SLAM-associated protein (SAP), 
GC TFH cell development is severely impaired (103).   
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The purpose of TFH cells is to provide stimulatory signals to B cells that have the highest 
affinity for the antigen within the GC (52). This is achieved by indirectly sensing affinity 
through the number of loaded MHC class II molecules on the B cells surface. The higher the 
affinity of the BCR, the more antigen it can acquire which means it can present more antigen 
on MHC class II and receive more TFH cell help. Help is provided by TFH cells with CD40L 
stimulation of CD40 on B cells and by cytokines such as IL21. Additionally, depending on 
the pathogen B cell antibody types can be tailored by the secretion of certain cytokines, IFNγ 
(Th1) and IL4 (Th2) (104). TFH cells have recently emerged as key players in developing 
protective vaccine responses and are currently under intense pre-clinical and clinical 
investigation.  
4.5 CIRCULATING T FOLLICULAR HELPER CELLS  
 
It has been difficult to study TFH cells in humans since the collection of secondary lymphoid 
organs where they reside is an invasive procedure. Recently a subset of CXCR5+PD1+ cells 
in circulation have been termed circulating TFH cells (cTFH). These TFH like cells could help 
the study of TFH cells in human health and disease since blood is easily accessible. Although 
BCL6 is required for the generation of cTFH cells they do not express BCL6 once in 
circulation (105-107). However, they do express the transcription factor c-Maf, which can 
upregulate CXCR5 and induce IL-21 production (107). cTFH cells can be further divided 
based on CXCR3 and CCR6 expression; CXCR3+CCR6- cTFH1, CXCR3-CCR6- cTFH2 and 
CXCR3-CCR6+ cTFH17 cells (108). Since mice and humans that lack the SAP protein needed 
for final TFH cell differentiation in the GC still have unchanged numbers of cTFH cells, it is 
believed that cTFH cells are generated before entry to GCs (109). It is believed that their 
primary function is to differentiate into GC TFH cells upon antigen re-exposure to enhance 
antibody responses (109). cTFH1 are found in circulation after influenza vaccination and 
correlate with high avidity antibodies (110, 111). cTFH2 cells are found after HPV vaccination 
(112) and Malaria infection (113). cTFH17 cells were induced by vaccination with a 
recombinant vesicular stomatitis virus expressing Ebola virus antigens, capable of replication 
(114). CXCR3- cTFH2/17 cells were found to correlate with broadly neutralizing antibodies 
in HIV+ individuals (107). Much remains to be elucidated on the origin and function of cTFH 
cells and their role as biomarkers for diseases and vaccine-efficacy. 
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Figure 3: Overview of the germinal center reaction. 
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5 VACCINE ADJUVANTS 
 
5.1 HISTORY AND DISCOVERY OF ADJUVANTS 
 
Adjuvants are included in vaccines to enhance the immune response against antigens 
included in the vaccine. As previously mentioned this is of particular importance for protein 
subunit vaccines that lack other immunostimulatory molecules from the pathogen. Already 
in 1921, it was shown that the immune response against a diphtheria toxin vaccine could be 
enhanced by the addition of insoluble aluminum salts (this adjuvant group will hereafter be 
called Alum for simplicity) (115). In the 1950s a new adjuvant reached clinical use, a water-
in-oil emulsion called Freund’s incomplete adjuvant (116). Although it improved the efficacy 
of influenza vaccines, its use was discontinued due to side effects such as sterile abscesses. 
It would take until 1997 until a new adjuvant besides Alum was licensed for human use (117). 
This was an oil-in-water emulsion adjuvant called MF59. As for Alum, MF59’s adjuvant 
effects were discovered by chance rather than by design. This trend of “luck” as the driver of 
adjuvant discovery was broken by the design of TLR agonists as adjuvants. A proof of 
concept that TLR agonists work was shown by the cream imiquimod (TLR7/8 agonist), 
which is licensed for topical use against actinic keratosis (118), basal cell carcinoma (119) 
and genital warts caused by HPV 1, 2, 4, and 7 (120). Shortly after the implementation of 
imiquimod, AS04 was released as an adjuvant in vaccines for human papillomavirus and 
hepatitis B virus (121, 122). AS04 consists of Alum and Monophosphoryl Lipid A, a TLR4 
agonist which interacts with TLR4 similarly to lipopolysaccharides of bacteria (123). A 
synthetic version of Monophosphoryl Lipid A has also been made called Glucopyranosyl 
Lipid A (GLA), which was used in paper II-III of the thesis. Since our understanding of the 
signaling pathways of the immune system has dramatically increased, we are now in an 
unprecedented position to develop and test new adjuvants. This has caused some to say that 
we have entered a new golden age of vaccine adjuvant development. 
 
Although the antigen used in paper I of this thesis was the HIV-1 Env glycoprotein, the 
primary research focus was the immune events that determine the quality of a vaccine. In the 
case of protein subunit vaccines this is likely primarily achieved by the adjuvants. As such, 
comparing the different immune responses induced by the adjuvants in vivo was the main 
focus of study I. An introduction to some of the known mechanisms of action of each adjuvant 
included in the thesis will be discussed below. 
 
5.2 ALUMINUM ADJUVANTS (ALUM) 
 
As mentioned, Alum is the oldest and most commonly used adjuvant. Pope and Glenny 
discovered that Alum could pull down toxins from solutions and then discovered that it also 
enhanced the immune response to toxins in guinea pigs (124). Hence its implementation was 
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used long before the mechanisms of action where discovered. Due to its long and widespread 
use, it has an extensive safety record. It is used in the national vaccination programs for many 
clinically approved vaccines.  
 
It has been known since long that Alum and similar adjuvants induce infiltration of immune 
cells to the site of injection (125-127). At the site of injection, fibrinogen is converted to 
fibrin, which along with neutrophil extracellular traps creates a meshwork where Alum is 
trapped  (21, 128-130). It has been proposed that Alums adjuvanticity is therefore conferred 
through a “depot effect” or the DNA from the neutrophil extracellular traps. None of these 
theories seem to provide a satisfactory explanation of the adjuvant effect of Alum in 
subsequent studies, especially the depot effect since the removal of the vaccine injected site 
shortly after immunization and thus any antigen depot did not affect the vaccine response 
(131-133). The more likely theory is that Alum simply induces inflammation, for instance by 
lysing lysosomes, leading to release of lysosomal enzymes into the cytoplasm (133-135). 
Inflammation induced by Alum leads to the production of cytokines and chemokines that 
recruit and activate more innate immune cells (136). Alum has also been shown in several 
studies to activate the NALP3 inflammasome, which leads to the production of IL-1β that 
stimulates T cell responses (137-139). Although some have modeled this as Alums main 
mechanism of adjuvanticity, it could not be confirmed by others (139, 140). Different mouse 
models, routes of vaccine delivery, the antigen of choice and more makes it difficult to 
pinpoint the exact mechanism of action for Alum or any other adjuvant. The differences in 
the mouse and human immune system also make it hard to know how translatable these 
results are. More information is warranted on the mechanisms of action of our most widely 
used adjuvant. 
 
5.3 MF59 
 
The mechanisms of action of MF59 has been extensively studied since its implementation in 
1997, although a lot of details remain to be elucidated. The adjuvant has now been given 
hundreds of millions of times and has proven to be safe and efficient. One particular 
advantage has been the improvement of influenza vaccination for the elderly, who respond 
poorly to un-adjuvanted influenza vaccines (117). Similar to the elderly, children also 
respond poorly to un-adjuvanted influenza vaccines and MF59 has been shown to increase 
the vaccine response in young individuals (141, 142). By increasing the efficacy of the 
vaccine, MF59 adjuvanted vaccines can use a lower antigen dose and require fewer 
vaccinations while remaining effective (143, 144). Additionally, MF59 has been shown to 
increase the breadth of the immune response, which is important in influenza vaccine 
contexts to protect against heterologous strains (145). 
 
In several studies, MF59 has been superior to Alum at generating vaccine responses (146, 
147). The depot effect hypothesis was falsified early on by investigating the clearance of 
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radiolabeled MF59 at the site of vaccination, which showed rapid clearance of both MF59 
and the antigen (148). Early studies also showed that MF59 could be found in LNs draining 
the vaccination site (149, 150). It seemed that most of this transport was done intracellularly 
and that APCs were the main cell type to transport the adjuvant (151). Upon direct stimulation 
with the adjuvant in vitro, the cells that respond the most are monocytes, macrophages and 
granulocytes, and they all respond similarly by the production of chemokines (117). The 
precise mechanism of how MF59 activates the cells is still unknown, although TLRs and the 
NALP3 inflammasome do not seem to play a part (152, 153). It appears that as with Alum, 
although by different means, MF59 induces inflammation at the site of injection that is crucial 
for its adjuvanticity. Consistently, the genetic profiles of MF59, Alum and CpG have been 
compared with the general finding that MF59 induces a broader range of inflammatory genes, 
many encoding for cytokines and chemokines (136). This response is local as the injection 
of adjuvant into non-vaccinated sites does not confer adjuvanticity (148). Preliminary studies 
have suggested MyD88 and apoptosis-associated speck-like protein containing CARD as 
crucial for MF59 adjuvanticity (152, 153). Much remains to be elucidated on the mechanisms 
of action of MF59 and on how much of the data from murine studies is translatable to humans. 
 
5.4 ALUM-TLR7 
 
In this thesis, we tested a new promising adjuvant formulation which combines Alum with a 
TLR7 agonist. This had previously been shown to be superior to Alum in generating antibody 
responses (146). A potential synergistic effect might be found from these adjuvants since 
Alum excels at inflammation and cell recruitment while TLR7 can directly activate cells such 
as B cells and DCs. Alum-TLR7 is not yet in clinical use and more information is needed on 
the innate and adaptive immune profiles induced by this adjuvant. In Paper I, we compared 
it side by side to Alum alone and to MF59. 
 
5.5 GLA 
 
GLA activates TLR4 in a similar fashion to LPS (154, 155). It has been shown to induce a 
Th1 like profile in mice and has been safe to administer in higher species (156-158). In study 
II-III of this thesis the GLA was used to evaluate if there was a need for an adjuvant with the 
administration of mRNA vaccines.  
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6 NUCLEIC ACID VACCINES 
6.1 DNA VACCINES 
 
Nucleic acid vaccines consist of either DNA or mRNA encoding specific antigens (41). Of 
the nucleic acid vaccines, technology for producing viable DNA vaccines has been available 
the longest, and there is an extensive literature on them (159). DNA vaccines function by 
being transcribed to mRNA which is then translated to a protein that the immune system 
recognizes. DNA therapeutics has shown potential for a long time, with a major breakthrough 
in 1992, when it was shown that a DNA vaccine could induce antigen-specific antibody 
responses. Still, there is no licensed human DNA vaccine available today (160). However, 
there is a DNA vaccine licensed for West Nile-virus in horses (161). One of the major 
advantages of DNA vaccines over conventional vaccines is that they can be produced 
synthetically, at a lower price than most vaccines, and are easier to transport (159). In addition 
DNA vaccines have been repeatedly shown to induce both humoral and cellular immune 
responses, making the platform promising for both infectious diseases and cancer vaccine 
therapeutics (162). However, there are several pitfalls with the DNA vaccination strategy that 
has likely slowed down its clinical application. Since DNA needs to enter the cell nucleus, 
DNA vaccines require either a viral vector or advanced delivery techniques (159). Also, pre-
existing immunity to the viral vector and logistical problems with advanced delivery methods 
makes DNA vaccines less ideal for large scale vaccination. There is also a concern of the 
incorporation into the genome causing unknown consequences or the development of 
antinuclear antibodies, inducing autoimmunity (159, 162). It remains to be seen what future 
DNA vaccines has for veterinary and human use. Will it soon show its true potential or will 
it be mRNA vaccines that live up to the promises of nucleic acid vaccination? 
 
6.2 mRNA VACCINES 
 
The literature of evidence showing the efficacy of mRNA vaccines is steadily growing (13). 
mRNA was first discovered as a carrier of genetic information in 1961 (163). In 1990 it was 
shown that mRNA injected into mice produced translated proteins (164). There were early 
problems with translation however since administered mRNA is recognized by the innate 
immune system via TLR 3, 7 and 9, leading to its degradation (165-167). Since administered 
mRNA molecules were quickly degraded and therefore did not yield high protein output, the 
potential of mRNA vaccines could not be unlocked. A major breakthrough was achieved in 
2005 when it was discovered that modification of synthetic mRNA, for instance by 
methylation mimicking that of natural mRNA, could greatly reduce TLR activation (168). 
Other improvements to the synthetic mRNAs were the additions of 5’ and 3’ untranslatable 
regions which increased stability and translatability of the mRNA, and the addition of the 5’ 
cap region protecting the mRNA from exonucleases (169-171). These discoveries, among 
others, unlocked the potential of mRNA vaccines and several immunogenicity studies follow 
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suit, showing induction of protective titers in animal models (172). Additionally, it was 
shown that by delivering the mRNA vaccines in lipid nanoparticles (LNPs) the immune 
response could be further enhanced (173).  
 
There are two main categories of mRNA vaccines, “normal” and self-amplifying. Self-
amplifying mRNAs translate RNA-dependent RNA polymerases, which in turn makes 
negative copies of the self-amplifying mRNA that is used to produce more mRNA. This in 
vivo amplification has the advantage of lowering the dose needed to achieve sufficient 
protein translation. Also, the replication of the mRNA can trigger innate immune pathways 
which can have an adjuvant effect (174). This thesis contains mRNA vaccines that are 
“normal” i.e. not self-amplifying. mRNA vaccines can be given intramuscularly (IM) or 
intradermally (ID) similarly to live or subunit vaccines. There are three main delivery 
formulations for mRNA therapeutics; naked RNA-, conjugate- or nanoparticle-delivery 
(175). Since entry to the cytoplasm is sufficient for translation of mRNA, the proportion of 
translation is higher than for DNA vaccines, which need entry into the nucleus of the cell. 
 
A particularly useful area where mRNA vaccines could be applied is influenza vaccination. 
The WHO tries to estimate what strains of influenza will be circulating each year and gives 
recommendations on which strands of influenza should be included in the yearly vaccine. 
mRNA vaccines can be produced within weeks, which offers an advantage over the more 
slowly produced sub-unit vaccines, such as the trivalent influenza vaccines (175). Subunit 
vaccines are not only slow to produce, but errors in the purification of the proteins can result 
in whole batches being discarded, leaving society without a vaccine until the next batch can 
be produced. Also, influenza still poses a pandemic threat and more effective means of 
dealing with pandemic influenza are desperately needed. For instance, it is estimated that up 
to 100 million people died by “the Spanish flu” in 1918. As comparison 37 million people 
died as a consequence the first world war (176). Due to the reasons mentioned above, quick 
scalable production of influenza vaccines is key to global health, which makes mRNA 
vaccines suitable candidates for vaccination against this pathogen. The mRNA vaccine 
platform developed by Moderna Therapeutics was shown to induce HA inhibition titers 
above the level of protection against influenza HA in both mice, ferrets, NHPs and humans 
(177). In project II-III we got the chance to further analyze their mRNA vaccine platform for 
influenza by focusing on characteristics of the innate and adaptive immune response induced. 
Basic research on the immune events occurring in vivo after mRNA vaccine administration 
is needed to improve future development and implementation of mRNA vaccines. 
7 NHPs AS A MODEL FOR VACCINATION 
 
To improve human and animal health and to prevent future catastrophes caused by 
pandemics, continued vaccine research is needed. For every experiment, careful ethical 
consideration should be applied to make sure that the benefits are believed to outweigh 
potential harm caused by experimentation. Since biology is extremely complicated, in vivo 
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models are crucial for improving our understanding of vaccines. It is our obligation to make 
sure that any harm to animals is minimized which is summarized by the three R’s. Reduce, 
which implies that the minimum number of animals needed to provide satisfactory data 
should be used. Refine, which implies that researchers should strive for proper planning 
before starting animal experiments, removing unnecessary repeat experiments. Refine also 
implies to ensure proper animal care from the animal’s birth until death. And replace, which 
implies that whenever a non-animal model or an animal model which is believed to cause 
less suffering for the animal, can be used to gather the same data, that model should be used 
instead. Most vaccine studies are done in mice. Mice are ideal for hypothesis testing, 
knockout experiments and allow for precise control of the environment and other factors. 
Mice, however differ from humans in many of their cell types, frequencies and expression of 
PRRs and other molecules. Their anatomy is also vastly different from that of humans. 
Vaccines are often given intraperitoneally in mice experiments rather than IM as in humans 
since the muscles of mice are very small. This makes results in mice hard to translate to 
humans. In this thesis, all vaccines are already in clinical use or likely to be used in the near 
future. They have already been tested in other preclinical studies. To gain insight that is truly 
translational we used the NHP model to test new hypotheses and to confirm those that have 
been tested in mice. NHPs have similar anatomy to that of humans. Their immune system is 
very comparable to that of humans with similar PRRs. Another advantage of the NHP model 
is that most markers used are cross-reactive to human, which means the same reagents can 
be used for both NHP and human studies. 
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8 MATERIALS AND METHODS 
 
The main methods of the thesis will be outlined below. Methods are described in greater 
detail within the individual papers.  
8.1 IMMUNIZATIONS 
 
Approval for study I was granted by the Animal Care and Use Committees of the Vaccine 
Research Center, National Institutes of Health (NIH). Study II-IV was approved by the Local 
Ethical Committee on Animal Experiments (Stockholm, Sweden). Animals were housed at 
BIOQUAL or the Division of Veterinary Resources, NIH in USA for study I. Animals were 
housed at Astrid Fagraeus Laboratory at Karolinska Institutet, Sweden, for study II-IV. All 
above according to guidelines of the Association for Assessment and Accreditation of 
Laboratory Animal Care.  
 
In study I, animals were given 1 ml IM vaccinations at four different sites. Vaccines 
contained either 100 µg of fluorescently labeled Env alone or mixed with fluorescently 
labeled MF59 at a 1:1 ratio, or adsorbed to 1 mg of alum or alum-TLR7. Animals also 
received adjuvant alone or PBS as controls at separate sites. Detailed vaccination schedules 
are outlined in results and discussion and in the papers. 
 
In study II-III animals received a LNP/H10 mRNA vaccine (50 µg). This was administered 
either ID or IM with or without the inclusion of the GLA adjuvant (5 µg). For innate immune 
tracking animals were also vaccinated with an Atto-655 labeled LNP/mCitrine mRNA 
vaccine (50 µg). Detailed vaccination schedules are outlined in results and discussion and in 
the papers. 
8.2 PROCESSING OF TISSUES 
 
Peripheral blood mononuclear cells (PBMCs) were collected via a ficoll density gradient. 
Muscles were processed and digested using Liberase as previously described (178). Liberase 
TH (0.26 WU/ml, Roche, Indianapolis, IN, USA) together with DNase (0.1 mg/ml, Sigma) 
was used to digest skin, for 1 hour in 37 °C under agitation. Complete media was used to 
quench the Liberase activity. Skins were filtered using 70 mm cell strainers (BD, Stockholm, 
Sweden) and were subsequently washed with PBS before being stained for flow cytometry. 
Scissors were used to mince LNs before mechanically pushing them through 70 mm cell 
strainers with a plunger. LNs cells were subsequently washed and stained for flow cytometry.  
8.3 FLOW CYTOMETRY STAININGS 
 
Cells were first stained with LIVE/DEAD Fixable Dead Cell kit (Invitrogen). Depending on 
the experiment, cells were then stained with different combinations of fluorescently labeled 
surface markers. When intracellular staining was performed, cells were permeabilized with 
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either Cytofix/Cytoperm™ (BD) (Study I-III) or transcription factor buffer set (BD) (Study 
IV) according to manufacturer’s instructions. 
8.4 IMMUNOHISTOLOGY STAININGS 
 
Tissues embedded in optimal cutting temperature embedding media were thawed from -80 
°C to -20 °C. Approximately 7 µm thick sections were obtained using a CryoStarTM cryostat. 
Slides were allowed to dry for 15 minutes before being fixed in 2 % formaldehyde solution 
diluted in PBS. Slides were blocked with fetal calf serum and permeablized using a triss-
buffer saline and saponin (2 %) based permeablilization buffer. Slides were subsequently 
stained with unconjugated primary antibodies, followed by biotinylated secondary 
antibodies. The secondary antibodies were visualized by the addition of streptavidin 
conjugate fluorophores. Images were acquired using a Nikon Eclipse Ti-E motorized 
confocal microscope.  
8.5 ANTIGEN RECALL ASSAY 
 
To test for antigen specific cells, PBMCs were re-stimulated in vitro. For study II-III H10 
overlapping peptides (matching protein from mRNA of previously administered vaccines) at 
2 µg/ml concentration and Brefeldin A were used for over-night stimulation and cytokine 
retention respectively. Cells were then stained for surface markers and cytokines to assess 
antigen specificity. 
8.6 ELISA 
 
For detection of antigen specific IgG, clear flat-bottom immune 96-well plates 
(Thermofisher) were coated with 100 ng of H10 protein for 3 h in 37 °C. Coated wells were 
washed and blocked for 1 hour with 2 % milk powder diluted in PBS (blocking buffer). 
Plasma samples diluted in blocking buffer were incubated in wells at 37 °C for 1 h. For 
avidity ELISAs an additional step was added with sodium thiocyanate (NaSCN) at 1.5-4.5M. 
Antibodies were then detected with an anti-monkey IgG HRP antibody (Nordic Labs) diluted 
in washing buffer (0.05 % Tween 20 in PBS). TMB solution (BioLegend) was used to detect 
the HRP antibody. Plates were read at 450 nm using an ELISA reader (PerkinElmer). 
8.7 B CELL ELISPOT 
 
B cell ELISpot was used to enumerate antigen-specific memory B cells and plasma cells as 
previously described (179). Briefly, plates were coated with anti-human IgG for detection of 
antibodies from stimulated memory B cells or unstimulated plasma cells. Antibodies were 
then detected via the addition of HA (antigen specific IgG) or anti human IgG (total IgG). 
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8.8 HEMAGGLUTININ INHIBITION ASSAY 
 
Turkey red blood cells diluted in PBS to 0.5 % were used to evaluate HA inhibition by serum 
antibodies. Non-specific blocking of agglutination was prevented by incubating serum with 
receptor destroying enzymes over night at 37 °C. Serial dilutions of the serum was used to 
evaluate its inhibition efficacy against agglutination of the red blood cells by HA from 
H10N8 influenza A virus.  
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9 RESULTS AND DISCUSSION 
9.1 IMMUNE MECHANISMS OF VACCINE ADJUVANTS (PAPER I) 
 
As mentioned above, little is known of the mechanisms of action of vaccine adjuvants. An 
improved understanding of how adjuvants work and the type of responses they induce would 
facilitate the development of new, improved adjuvants and better match adjuvants with 
specific diseases. In the first study of my thesis, which I entered as a master’s student and 
early Ph.D. student, we aimed to compare the first immunological events occurring in vivo 
after administration of three distinctly different adjuvants. We chose to study Alum combined 
with a TLR7-agonist (Alum-TLR7) and the oil-in-water emulsion adjuvant MF59. They had 
both been shown to induce high antibody titers and T cell responses compared to many other 
adjuvants tested side-by-side in NHPs in a prior study led by our collaborators (180). We also 
included the conventional adjuvant Alum as a benchmark. The adjuvants were administered 
together with the HIV vaccine candidate envelope glycoprotein gp120 (Env) since this 
antigen is well characterized and tested in both preclinical and clinical vaccine trials and is 
relevant together with these adjuvants. The adjuvants and Env were provided by Novartis 
(now Glaxo Smith Kline; GSK) which means that they had been quality control tested and 
formulated according to their standards. 
 
Studies on the mechanisms by which adjuvants work have previously mostly been performed 
in mice, however, such results are not always translatable to humans (181-183) especially 
since mice have a different expression repertoire of TLRs compared to humans and NHPs. 
To build on the knowledge gained from the murine studies, we therefore used rhesus 
macaques since they have an immune system and anatomy more similar to humans.  
  
The overall purpose of Paper I was to evaluate 
how the distinctly different adjuvants influenced 
the initial immunological steps after vaccine 
administration such as mobilization of cells, cell 
activation, vaccine antigen uptake and 
presentation. Additionally, we aimed to 
characterize early adaptive events initiated by 
innate immunity, such as the formation of GCs 
which was my primary focus in the study. 
Therefore, a lot of the analyses were on the 
immune responses at the site of injection and in 
the vaccine draining LNs. Animals were divided 
into four groups receiving either Alum, Alum-
TLR7, MF59 or no adjuvant together with Env. 
Each animal received four injections, i.e. in the 
left and right deltoid or quadriceps muscle with 
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either adjuvant together with Env, adjuvant alone or PBS. This experimental set up allowed 
for that each animal had their own PBS control and that we could restrict the number of 
animals used for experimentation. Sample collection was performed at termination at 2 hours, 
24 hours, 72 hours or 10 days after immunization. 
 
The recruitment of immune cells to the site of vaccine administration is a prerequisite to 
stimulate efficient vaccine responses (184). This is especially important for administration 
sites such as the muscle, which contains very few immune cells at steady state (16, 178). As 
mentioned earlier, protein subunit vaccines need adjuvants since they often lack 
immunostimulatory properties and are poorly immunogenic themselves. In line with this, we 
found that infiltration of immune cells to the site of injection or vaccine-draining LNs was 
only induced in the presence of adjuvants, as it was very limited at sites injected with PBS or 
Env alone. Neutrophils and monocytes were the most abundant cells to infiltrate the injection 
sites. Similar to data from murine studies (150), we found that the infiltration of immune cells 
in both muscle and LNs was rapid and transient with the highest numbers detected at 24 hours 
with a decline at 72 hours (Figure 4). Overall, MF59 and Alum-TLR7 generated stronger 
infiltration of immune cells e.g. myeloid cells such as neutrophils, monocytes and myeloid 
DCs to the site of injection and to vaccine-draining LNs compared to Alum.  
 
In order to track vaccine uptake and its distribution, Env was labeled with the fluorescent dye 
Alexa680. Env+ cells were readily detected at the site of injection and exclusively in the LNs 
draining the site of injection, indicating that the dissemination of vaccine antigen was very 
local (Figure 5). Neutrophils and monocytes again represented the most frequent cell 
populations that took up the antigen (Env+), likely due to their high phagocytic abilities and 
their abundance. While there was no statistical difference in antigen uptake between the 
adjuvant groups, the animals receiving MF59 showed more Env+ neutrophils in the vaccine-
draining LNs as well as more neutrophil migration in general to these sites. While both MF59 
and Alum-TLR7 induced recruitment of PDCs to the vaccine-draining LNs, only the Alum-
TLR7 group showed antigen uptake by PDCs at a higher level.  
 
Figure 5: Uptake of antigen (Env) in vivo in the presence of MF59, Alum or Alum-TLR7 
adjuvant by MDCs at the site of injection and draining LNs.  
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The TLR7 receptor detects single-stranded RNA and its activation is known to result in the 
induction of high levels of type I IFN and skewing towards Th1 responses (185, 186). Hence, 
we expected to find evidence of type I IFN production in the Alum-TLR7 group. We used 
detection of the MxA protein as a surrogate marker for type 1 IFN production since MxA 
expression is tightly regulated by type I IFNs (187). MxA was only detected at the site of 
injection and in vaccine-draining LNs in the animals in the Alum-TLR7 group (Figure 6A). 
Additionally, only Alum-TLR7 induced PDCs to produce type 1 IFN in vitro (Figure 6B). 
 
In line with the type I IFN milieu induced by Alum-TLR7 we also detected a predominant 
Th1 type CD4+ T cell response characterized by IFNγ in this group (Figure 7). In contrast, 
MF59 induced a mix of IFNγ (Th1) and IL4 (Th2) producing CD4 T cells.  
 
Ultimately the strength of a vaccine is 
determined by the quantity, quality, longevity 
and breadth of the antibodies induced. All of 
these are the product of a strong GC response. 
To analyze the GC response in vaccine-
draining LNs we developed a staining protocol 
using CD3, PD1 and Ki67. GCs were defined 
as clusters of GC B cells (CD3-Ki67+) and TFH 
cells (CD3+PD1+). We confirmed that CD3-
Ki67+ cells were GC B cells by their expression 
of CD20. The software CellProfiler™ was used 
together with a customized algorithm to 
enumerate cells within GCs and to measure the 
area of the GCs. We found that the animals 
receiving Alum-TLR7 and MF59 showed 
Figure 6: MxA expression is only induced by Alum-TLR7 at the site of injection and in 
draining LNs and only Alum-TLR7 induces type 1 IFN production by PDCs in vitro. 
 
A B 
Figure 7: Cytokine ELISpot on PBMCs after 
vaccination with different adjuvants. 
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equally strong induction of GCs and were both superior over Alum (Figure 8). This pattern 
was found for GC area and TFH cells for both MF59 and Alum-TLR7, while only MF59 had 
statistically higher numbers of GC B cells over Alum.  
 
Therefore, although MF59 and Alum-TLR7 have distinctly different innate immune profiles; 
MF59 inducing a mixed Th1/Th2 response with enhanced neutrophil recruitment and Alum-
TLR7 a strict Th1 profile with type I IFN production, they both demonstrated enhanced GC 
activity. The requirements for the initiation of a GC reaction basically involves four essential 
processes (which could be simultaneous events); 1. the transport of antigen to FDCs in B cell 
follicles, 2. retention of antigen within these follicles, 3. activation of innate immune cells 
e.g. monocytes or DCs with production of cytokines and antigen presentation to T cells, and 
finally, 4. the activation of T cells and B cells to enter the GC. These processes can be 
influenced by different factors in the LN milieu. In our study, we speculated that the strong 
neutrophil recruitment by the MF59 adjuvant or type I IFN production and activation of 
immune cells induced by Alum-TLR7 affected these processes. However, the depletion of 
neutrophils has been shown to not reduce the adjuvant effect of MF59 in mice (150). This 
may mean that other immune cells e.g. monocytes could compensate for the loss of 
neutrophils. In any event, there are several potential mechanisms by which neutrophils could 
enhance the immune response to vaccines, such as the production of chemokines that recruit 
other immune cells to the site and cytokines, including BAFF for support of B cell survival. 
Neutrophils can also contribute with transportation of antigens and even antigen presentation 
(47, 188).  
 
Similarly, it remains to be elucidated to what degree Alum-TLR7 adjuvanticity is achieved 
by direct TLR activation or by the indirect effect of type I IFN production (189, 190). Naïve 
B cells have low or no expression of TLRs, however BCR activation and differentiation into 
memory B cells induce expression of TLR 2, TLR6, TLR7, TLR9 and TLR10 (191). Hence, 
Figure 8: Section of a vaccine-draining LNs stained for germinal centers. The 
graphs to the right show that MF59 and Alum-TLR7 are superior at the induction 
of GC responses over Alum. 
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although TLR stimulation can lead to polyclonal activation of memory B cells, with the 
production of Igs, and even provide a mechanism for sustaining the memory B cell pool, it is 
not enough for the activation of naïve B cells (192). T cell-dependent activation of naïve B 
cells requires three essential steps: 1. Binding of antigen to the BCR, 2. Activation by CD40L 
from cognate CD4 helper T cells, 3. Additional stimuli as provided by TLRs (191). Previous 
studies in mice have shown that TLR7 stimulation of B cells was sufficient to induce 
proliferation and IgG production, while type I IFN was required for fine tuning the isotype 
switching of antibodies (193). In our study and in most other contexts, TLR7 stimulation and 
type I IFN stimulation of B cells are processes that likely occur simultaneously. Either way, 
the differential immunological milieus identified with the different adjuvants in our study 
likely played a critical role in polarization of the Th1 vs Th2 responses with the different 
adjuvants. This could, in turn, result in different antibody isotypes produced, and ultimately 
decide whether a vaccine response is protective or not (194).  
 
A prior study investigating how potently these different adjuvants induce adaptive vaccine 
responses to Env had shown surprisingly small differences between Alum, MF59 and Alum-
TLR7 in terms of the level of SHM (180). This is in contrast to our findings where the larger 
GCs we detected in the Alum-TLR7 and MF59 groups presumably would generate more 
SHM. In agreement with this presumption, a separate study where we investigated a 
liposome-based Env vaccine found that the animals with superior neutralizing antibodies 
after vaccination also had the largest GCs (195).  
 
Collectively, the data from Paper I demonstrate that adjuvants generating stronger antibody 
responses, such as MF59 and Alum-TLR7 over Alum, have stronger innate immune 
responses leading to superior GC formation. We show that while MF59 and Alum-TLR7 
both reach strong end goals, such as high T cell and B cell responses including the formation 
of GCs, the innate immune profile leading up to this is very different. Alum-TLR7 induces 
type I IFN production, while MF59 induces the recruitment of neutrophils to vaccine draining 
LNs. It is plausible that the Alum-TLR7 and MF59 would be best suited to stimulate 
responses to different pathogens requiring different types of responses. Insights from this 
study may therefore help the future implementation of these adjuvants.  
9.2 INNATE AND ADAPTIVE RESPONSES TO mRNA VACCINES (PAPER II-III) 
 
The recognition of Paper I resulted in the opportunity to further develop our rhesus macaque 
model to study the early immune mechanisms induced by mRNA vaccines. Since the field 
of mRNA vaccines is in its infancy there is limited knowledge of the innate and adaptive 
immune responses they induce. The aim of Paper II-III was therefore to characterize in detail 
the immune responses by mRNA vaccines. In these studies, we collaborated with Moderna 
Therapeutics that designed and provided the mRNA vaccines.  
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In this project, the 
animals were divided 
into three groups 
receiving modified 
mRNA encoding the 
HA of H10N8 influenza 
A virus packaged in 
LNPs. One group 
received the vaccine ID 
one IM and the final 
group received the 
vaccine IM together 
with the TLR4-based 
adjuvant GLA. We 
found that all animals 
induced neutralizing 
antibody titers against 
HA above the reported level required for protection against influenza after vaccination 
(Figure 9). The addition of a GLA adjuvant showed no superior responses over the un-
adjuvanted vaccines. This indicated that the mRNA/LNP vaccine formulation was 
immunogenic in itself and did not need an adjuvant. It is possible that other adjuvants may 
have been able to enhance the vaccine responses, but we conjectured that the mRNA/LNP 
vaccine formulation induced sufficient innate immune activation to generate a potent immune 
response. We therefore set out to characterize the innate immune response induced after 
administration. For these experiments, we used an mRNA construct encoding for the 
fluorescent protein mCitrine (Paper II), enabling detection of the cells that had translated the 
mRNA. The mRNA was delivered in fluorescently labeled LNPs to enable identification of 
Figure 10: Infiltration of immune cells to the site of injection after mRNA LNP vaccine 
administration. 
 
Figure 9: HA mRNA vaccine delivered in LNPs induces high 
HAI titers, the dotted line indicates the threshold of protection.  
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cells that had taken up 
the vaccine and cells that 
had translated the 
mRNA. Similar to Paper 
I, samples were collected 
at different time points (4 
hours, 24 hours and 9 
days) after 
administration of the 
mRNA vaccine or PBS 
as a control.   
 
As found for 
protein/adjuvant 
administration in Paper I, 
the mRNA vaccine also 
induced rapid 
recruitment of immune 
cells to the site of 
injection, with the 
highest recruitment 
measured at 24 hours 
(Figure 10). Infiltration 
of immune cells was induced by LNPs regardless if it contained mRNA. As for the adjuvants 
tested in Paper I, the LNP/mRNA vaccine was mostly taken up by neutrophils and 
monocytes. However, for mRNA vaccines to function translation is required in addition to 
uptake. The majority of the cells translating the mRNA were found to be monocytes, followed 
by various DC subsets (Figure 11). In contrast translation by neutrophils was almost 
Figure 11: Uptake and translation of the LNP mRNA vaccine 
by immune cells at the site of injection and in draining LNs. 
 
Figure 12: mRNA vaccine administration leads to type I IFN production in vaccine 
draining LNs as shown by the production of the type I IFN inducible protein MxA. Scale 
bars are 200 µm. 
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negligible. As for the protein/adjuvant administrations in Paper I, the mRNA vaccine was 
also detected exclusively at the site of injection and the LNs draining the site of injection.  
 
Although the mRNA constructs used for vaccination has been modified to induce less innate 
immune activation in order not to interfere with translation efficiency, the recognition of the 
constructs by TLRs or other PRRs is not completely abolished (13, 168, 174). We used the 
expression of MxA as a surrogate marker for type I IFN production again. A clear 
upregulation of MxA at 24 hours after vaccination was found in the vaccine-draining LNs 
(Figure 12).  No MxA was found at 4 hours or 14 days after vaccination, indicating that the 
production of type I IFN in response to mRNA vaccination has a limited time frame. This 
fits well with the 
translation data showing 
peak translation at 24 
hours after vaccination 
in vaccine-draining 
LNs. Collectively paper 
II shows that LNP 
mRNA vaccines are 
immunogenic, induce 
rapid infiltration of 
immune cells with 
monocytes being the 
main cell type 
translating the vaccine. 
The vaccine response is 
restricted to the site of 
injection and vaccine-
draining LNs where the 
induction of type I IFN 
is promoted, 
presumably by TLR7 
activation by the 
mRNA.  
 
While type I IFN 
production is indicative 
of a Th1 response, the 
Th1/2/17 classification 
is ultimately centered 
around T helper cells 
with different effector 
functions, including the 
Figure 13: CXCR3+ cTFH cells are induced 7 days after vaccination 
and CXCR3+ TFH cells are proliferating in vaccine-draining LNs. 
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skewing of B cells to produce antibodies of different isotypes and qualities. In paper III we 
therefore focused on details of the adaptive immune response induced by mRNA vaccines, 
such as the phenotype and kinetics of the T cell and B cell response and the induction of GCs 
in vaccine draining LNs. 
 
In the animals receiving the influenza mRNA vaccine we therefore investigated whether 
detectable levels of circulating TFH cells were induced and whether they showed a polarized 
phenotype based on the chemokine receptor CXCR3+(Th1) or CXCR3- (Th2/17). Strikingly 
there was only evidence of CXCR3+ cTFH1 cells and no increase of the Th2/17 populations 
(Figure 13 A-B). There was also a higher percentage of CXCR3+ TFH in the vaccine-draining 
LNs compared to control LNs, and those TFH were to a higher degree Ki67+, indicating that 
they were proliferating (Figure 13 C-D). Altogether, the data suggest that the mRNA vaccine 
induces a strict Th1 type phenotype, likely shaped by the strong type I IFN response.   
 
Biomarkers early after vaccination that predict long term protection are key to making 
vaccine research more efficient and to quickly assess the quality of the immune response in 
vaccinated individuals. It was recently shown that circulating TFH1 cells correlate strongly 
with long term avidity of influenza antibodies in humans (110). We thus investigated whether 
there was a similar pattern in our study. First, we analyzed antigen-specific IgG titers and 
antibody avidity and found that while IgG titers increased rapidly with each vaccination, 
antibody avidity increased slowly over time (Figure 14). We analyzed multiple time points 
and the latest time point in the study was around 38 weeks. We had samples available from 
Figure 14: H10 specific IgG titers and H10 specific IgG avidity index after mRNA vaccine 
administration.  
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this point from 6 animals and found that there was a strong correlation between the cTFH 1 
cells and antibody avidity (Figure 15). The mechanisms behind this correlation remain to be 
elucidated, but it is plausible that circulating TFH reflect the overall strength of conventional 
TFH activation within GCs.   
 
The induction of GCs was also evaluated by immunohistology in tissue sections (Figure 16). 
Each GC was evaluated separately and there was a clear increase in size and cell numbers of 
individual GCs 14 days after vaccination. Thus, we concluded that the mRNA vaccine was 
able to induce GC formation, enabling the formation of affinity matured memory B cells and 
long-lived plasma cells.  Since GCs take approximately 7 days to mature and it is in these 
that affinity maturation of antibodies occur, the delayed increase in antibody avidity index 
seen in Figure 14 can be naturally explained by GC kinetics (57). The avidity index will also 
increase as less competitive clones of antibodies are being depleted, while affinity matured 
antibodies remain. 
 
To further dissect the immune response, we investigated the kinetics of peripheral memory 
B cells and BM PCs by ELISPOT analysis, after vaccine administration (Figure 17). The 
memory B cell pool expanded and contracted with each immunization and seemed to plateau 
around week 15. To our surprise, plasma cells were found to be seeded already at two weeks 
after prime immunization. This indicates that GC formation occurs quickly after 
immunization since plasma cells homing to the BM are induced late in the GC reaction (196). 
After initial seeding, the number of plasma cells in the BM seemed stable, as the numbers 
did not fluctuate with the boost immunization, similarly to what has been reported by others 
(179). Much remains to be elucidated on how the maintenance of long-lived plasma cells in 
the BM is controlled. Do plasma cells with higher affinity against influenza HA that arrive 
in the BM after the boost immunization outcompete any lower affinity plasma cell clones? If 
that is the case, how is this selection process 
achieved? Plasma cells display little or no 
BCRs on their cell surface and can 
therefore not compete for antigen uptake 
like the process in a GC (197). Even if they 
could, the BM is not thought to harbor 
antigens to any great extent, as this would 
likely interfere with de novo generation of 
B cells since strong BCR activation in the 
BM of newly generated B cells leads to 
apoptosis, as protection against 
autoimmunity. Another scenario where 
new plasma cells would simply replace old 
plasma cells in the BM at random makes 
little sense. Since we know that some 
vaccines such as smallpox and yellow fever 
Figure 15: The frequency of cTFH1 cells is a 
vaccine biomarker for long term antibody 
avidity. 
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induce long-lived plasma cells that can survive over a lifetime and are not replaced by the 
continuous repopulation of new long-lived plasma cells created during an individual’s 
lifetime (198). This conundrum of plasma cell niches within the BM is an area that needs 
more research to improve future vaccine design strategies. 
 
Collectively Paper II and III shows that mRNA vaccines are immunogenic in a NHP model. 
The vaccine is mainly taken up by monocytes and neutrophils while most mRNA translation 
occurs in monocytes. The vaccine is immunogenic on its own and did not benefit from the 
inclusion of the GLA adjuvant. As mentioned earlier the use of mRNA for vaccination has 
become feasible due to modifications to make the mRNA more stable and less potent at 
stimulation of innate immunity. However, some innate immune activation may be necessary 
to induce vaccine responses, or otherwise, an adjuvant may be needed.  
 
Finally, the vaccine induces a Th1 skewed response, strong GC activation and strong 
antibody avidity that correlates strongly with circulating TFH1 cells. The skewing towards a 
Th1 profile might be beneficial for influenza vaccines in terms of antibody isotype produced 
since it has been shown in mice that Th1 skewed antibodies and not Th2/17 skewed 
antibodies protect against influenza infection, although they have the same affinity to bind 
antigen (194).  
Figure 16: mRNA vaccines induce strong GC reactions two weeks after boost vaccination. 
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9.3 A NOVEL METHOD FOR GC ANALYSIS BY IMMUNOHISTOLOGY THAT 
COMPARES TO FLOW CYTOMETRY 
 
The analysis of GCs is often applied in the study of vaccine immunology, autoimmunity and 
cancer. In Paper I and III of the thesis, the analysis of GCs was one of my main interests, 
since GCs are essential to the generation of long-lived vaccine responses and affinity 
maturation of antibodies. Since we were interested in tracking fluorescently labelled vaccines 
and analyze various effector molecules which are not always easily detected by flow 
cytometry, we opted to analyze vaccine draining LNs by immunohistology in some 
situations. We therefore developed a staining protocol to stain for GCs in NHP LNs. This 
protocol was used for paper I and III of this thesis, and a paper investigating a liposome-
based Env vaccine, not included in this thesis (195). We discovered that while there are 
established methods for the analysis of GCs by flow cytometry, there was no consensus on 
how to analyze GCs by immunohistology. Also, there was no data on how the two methods 
compare, which made comparisons between studies using the different methods difficult.  
 
The aim of Paper IV was therefore to address the lack of comparison between the methods 
and also the lack of consensus on how to analyze GCs by immunohistology. We compared 
the two methods within the same LNs. Eighteen mesenteric LNs were cut in half and each 
half was analyzed by either flow cytometry or immunohistology (Figure 18). 
 
GCs were detected by immunohistology by staining for T cells (CD3+), TFH (CD3+PD1+) and 
GC B cells (CD3-Ki67+). We confirmed that CD3-Ki67+ cells were B cells by their expression 
Figure 17: mRNA vaccine induces a potent humoral immune response with early induction 
of antibody secreting cells (ASCs) including BM plasma cells and circulating memory B 
cells. 
 
Weeks  
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of CD20 in a separate staining. Two consecutive sections from each LN were obtained and 
were stained for either CD3, PD1 and Ki67 or CD3 and CD20. The consecutive staining with 
CD20 was included since the number of B cells was needed to normalize GC B cell data and 
since all antibodies did not fit into one protocol. To analyze the images, we developed a 
custom-made algorithm for the analysis of GCs using the freely available CellProfiler™ 
software. Data was collected after manually confirming that cells were accurately counted in 
a few control LNs.  
The flow cytometry panel was designed in accordance with previous studies, using the 
minimum number of antibodies required for accurate detection of GC B cells and TFH cells 
(199, 200). Gating from live singlet cells, GC B cells were defined as CD3-
CD20+Ki67+BCL6+ and TFH cells as CD20-CD3+CD4+CXCR5+PD1++. 
 
The number of GCs in secondary lymphoid organs is often used as a readout in experimental 
setups (182, 183, 201). However, 
defining the precise number of GCs 
can be difficult, since GCs in close 
proximity are hard to discriminate 
and the minimum number of cells 
required to qualify as a GC is 
arbitrary (Figure 19). Also, if the 
number of GCs is considered, the 
data can easily be distorted and 
nonsensical. For instance, a LN with 
ten small GCs will score higher than 
one with eight large GCs. Instead, the 
total number of cells in GCs or total 
GC area can be used to measure GC 
activation, which more closely 
resembles data collected by flow 
cytometry. 
 
Figure 19: GC staining illustrating the difficulty in 
enumerating the precise number of GCs. 
 
Figure 18: Study layout for analysis of GCs with immunohistology and flow cytometry in 
the same LN. 
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The major aim of this study was to investigate what means of analysis by immunohistology 
related most closely to flow cytometry. In flow cytometry, cell numbers are often presented 
as % of live or % of parent. Similarly, data from immunohistology needs to be normalized 
by an appropriate factor. For immunohistology, we normalized GC cell numbers by the 
number of GCs or their parent cells, i.e. T cells or B cells, and GC area was normalized by 
LN area. This data was then compared to similar data acquired by flow cytometry. We found 
that using GC numbers as a means of normalization did not relate well to flow cytometry 
data, which could be due to the pitfalls with accurately counting GCs discussed above (Figure 
20A). Next, we compared GC area normalized by LN area to TFH cells or GC B cells 
normalized by total live cells by flow cytometry (Figure 20B). While GC area did not 
correlate with GC B cells by flow cytometry, it correlated well with TFH cells by flow 
cytometry. We previously established that TFH cells within individual GCs better correlated 
with the area of these GCs compared to GC B cells. This means that GC area better represents 
the number of TFH cells within them. This could explain why GC area correlates better with 
TFH by flow cytometry compared to GC B cells. Finally, we compared TFH cells or GC B 
cells normalized by parent cells to the same parameter by flow cytometry and found good 
correlations for both GC B cells and TFH cells (Figure 20C).  
 
Based on our findings, we propose to analyze GCs by immunohistology as; GC area % of 
LN area or total TFH cells or GC B cells % of parent, to enable comparable data to that of 
flow cytometry.  
Figure 20: Correlation of immunohistology and flow cytometry data of GCs within matched LNs. 
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